医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

REVOLVE™ Fat Grafting System by Acelity Now Available in Europe

2015年06月29日 PM10:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global wound care and regenerative medicine company, announced today that its patented REVOLVE™ System is now available in Europe. REVOLVE™ System offers fast, efficient and secure fat tissue processing in a range of reconstructive procedures. Fat grafting involves harvesting and transferring adipose tissue or body fat from one area of the body to another. The technique is gaining in popularity with surgeons because it uses the patient’s own tissue to enhance volume.

REVOLVE™ System is designed to yield rapid, reliable results in high-volume procedures through the use of a simple, closed system that controls critical variables in fat grafting. The single-use device can be placed in the sterile field to facilitate more efficient processing, filtering and transferring of a patient’s own (autologous) fat tissue. It enables high-volume fat processing (up to 700ml lipoaspirate) in less than 10 minutes, offering the potential to reduce operating room (OR) procedure time.

“With this European launch, Acelity continues to set global benchmarks in bringing cutting edge technologies to patients and setting the bar for standard of care in fat grafting,” said Lesley Fronio, Vice President and Franchise Leader of Breast Reconstruction and Fat Grafting at Acelity. “As a global leader in regenerative medicine, we continue adding to our portfolio of fat grafting products to provide clinicians with the tools they need to perform the most up-to-date procedures, efficiently and effectively.”

REVOLVE™ System has been used in multiple fat grafting surgeries. REVOLVE™ System uses surgical mesh specifically designed to filter blood debris and fluid to attain clean and high quality adipose tissue for transfer. The device also has a proprietary “collagen string catcher,” which helps prevent clogging within syringe tips during adipose re-implantation and effectively enhances procedural speed and proficiency.

“Fat grafting shows tremendous promise for the future of plastic surgery, as it uses patients’ own fat cells instead of foreign material implants,” said Mr. Ash Mosahebi, MBBS FRCS MBA PhD FRCS Consultant and Hon Senior Lecturer Royal Free Hospital, London, U.K. “REVOLVE™ System helps clinicians efficiently process high volumes of fat tissue to produce quality natural fat product, ultimately helping patients achieve more natural-looking results.”

Acelity is focused on changing the practice of medicine with transformative technology and providing innovative healing solutions that restore patient lives. For more information about the REVOLVE™ System features and benefits, visit LifeCell.com.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150629005191/en/

CONTACT

Acelity
Corporate Communications
Sarah Swift, +44 (0)797 0742
696
sswift@acelity.com
or
Investor
Relations
Caleb Moore, +1-210-255-6433
caleb.moore@acelity.com

同じカテゴリーの記事 

  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告
  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
  • SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
  • Oriola Partners With HCLTech to Enhance Customer Experience Through Digital Transformation